LAURA MAZILU, DANA LUCIA STANCULEANU, ANDREEA DANIELA GHEORGHE, ADRIAN PAUL SUCEVEANU, RAZVAN HAINAROSIE, IRINEL RALUCA PAREPA, OVIDIU BRATU, CAMELIA CRISTINA DIACONU, DANIELA MANUC, ANCA PANTEA STOIAN, ANDRA IULIA SUCEVEANU SPECIFIC ADVERSE EFFECTS OF BEVACIZUMAB IN THE TREATMENT OF NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) IN CLINICAL PRACTICE Lung cancer is the most common cause of cancer-related mortality, and non-small cell lung cancer (NSCLC) represents about 85% of all lung cancers. In the last years, novel targeted therapies have been developed and approved in the treatment of NSCLC. Angiogenesis is a very complex process, and cancer angiogenesis is the most important event concerning cancer growth, invasion and metastasis. VEGF signalling pathway plays a significant role in cancer angiogenesis, and it is demonstrated that VEGF levels are correlated with increased angiogenesis and with poor prognosis and metastasis in NSCLC patients. Bevacizumab is a recombinant humanised monoclonal IgG1 antibody, it is one of the first agent used for anti-angiogenic treatment, and it was approved for the treatment of non-squamous NSCLC in combination with chemotherapy.